Login

Dorieke Brink-Kwakkel

ORCID: 0000-0002-1826-3138
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
A5069127848
Research Areas
  • Big Data and Business Intelligence
  • Vaccine Coverage and Hesitancy
  • Research Data Management Practices
  • SARS-CoV-2 and COVID-19 Research
  • COVID-19 Clinical Research Studies
  • Scientific Computing and Data Management

University Medical Center Utrecht
 2023

 Effectiveness of homologous/heterologous booster COVID-19 vaccination schedules against severe illness in general population and clinical subgroups in three European countries
OPENALEX - Publications 
Fabio Riefolo Belén Castillo‐Cano Mar Martín‐Pérez Davide Messina Roel Elbers and 16 more Dorieke Brink-Kwakkel Felipe Villalobos Ylenia Ingrasciotta Patricia García-Poza Karin Swart-Polinder Patrick C. Souverein Luis Carlos Saiz Carlo Alberto Bissacco Leire Leache Michele Tari Salvatore Crisafulli Lamiae Grimaldi‐Bensouda Tiago Andres Vaz Rosa Gini Olaf H. Klungel Elisa Martín‐Merino

Using 4 data-sources (Spain, Italy, United Kingdom) data and a 1:1 matched cohort study, we aimed to estimate vaccine effectiveness (VE) in preventing SARS-CoV-2 infections with hospitalisations (±30 days) death (±56 general population clinical subgroups homologous/heterologous booster schedules (Comirnaty-BNT Spikevax-MOD original COVID-19 vaccines) by comparison unboosted individuals, during Delta beginning of Omicron variants. Hazard Ratio (HR, Cox models) VE ([1-HR]*100) were calculated...

10.1016/j.vaccine.2023.10.011 article EN cc-by Vaccine 2023-10-17
Coming Soon ...